11C-acetate PET/CT before radical prostatectomy: Nodal staging and treatment failure prediction

Journal of Nuclear Medicine

Volumn 54, Issue 5, 2013, Pages 699-706

  Haseebuddin, Mohammed ^a   Dehdashti, Farrokh ^b,c   Siegel, Barry A ^b,c   Liu, Jingxia ^a   Roth, Elizabeth B ^a   Nepple, Kenneth G ^a   Siegel, Cary L ^b,c   Fischer, Keith C ^c   Kibel, Adam S ^a,b   Andriole, Gerald L ^a,b   Miller, Tom R ^b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetate; Cancer staging; Lymphatic metastasis; PET; Prostatic cancer

Indexed keywords

ACETIC ACID C 11; PROSTATE SPECIFIC ANTIGEN; ACETIC ACID; ACETIC ACID DERIVATIVE; CARBON; CARBON-11 ACETATE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; ANALYSIS OF VARIANCE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; PET; PROSTATE TUMOR; RISK; SCINTISCANNING; VERY ELDERLY;

ACETATE; CANCER STAGING; LYMPHATIC METASTASIS; PET; PROSTATIC CANCER;

ACETATES; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARBON; DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK; TREATMENT FAILURE;

EID: 84877102488     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.111153     Document Type: Article

References (34)

1. Gallina A, Chun FK, Suardi N, et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int. 2008;101:1513-1518. (Pubitemid 351704026)
2. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117-1123.
3. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095-1101. (Pubitemid 46891611)
4. Parker CC, Husband J, Dearnaley DP. Lymph node staging in clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 1999;2:191-199. (Pubitemid 30055533)
5. Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387-395.
6. Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol. 2009;55:761-769.
7. Briganti A, Chun FK, Salonia A, et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol. 2006;49:1019-1026.
8. Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003;170:1798-1803. (Pubitemid 37254931)
9. Bishoff JT, Reyes A, Thompson IM, et al. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology. 1995;45:270-274.
10. Briganti A, Chun FK, Salonia A, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol. 2006;50:1006-1013. (Pubitemid 44486500)
11. Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51:1511-1520.
12. 18fluorine-labeled deoxyglucose. J Urol. 1996;155:994-998.
13. 11C-choline. J Nucl Med. 2011;52:81-89.
14. 11C- acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med. 2008;49:327-334.
15. 11C-acetate whole-body PET. J Nucl Med. 2004;45:1233-1236.
16. 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003;30:607-611.
17. Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1380-1384. (Pubitemid 44392221)
18. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181-186.
19. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44:549-555.
20. Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PU. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology. 2006;67:996-1000. (Pubitemid 43956436)
21. 11C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:181-184.
22. Wolf JS Jr. Cher M, Dall'era M, Presti JC Jr. Hricak H, Carroll PR. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol. 1995;153:993-999.
23. 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol. 2011;60:125-130.
24. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9:230-234. (Pubitemid 44317255)
25. 11C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging. 2007;34:185-196.
26. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med. 2003;44:331-335. (Pubitemid 39586006)
27. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008;54:392-401.
28. 11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin. 2003;42:25-30.
29. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925-933.
30. Womble PR, VanVeldhuizen PJ, Nisbet AA, Reed GA, Thrasher JB, Holzbeierlein JM. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. J Urol. 2011;186:882-887.
31. Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003;62 (suppl 1):55-62. (Pubitemid 41116563)
32. U.S. Food and Drug Administration Web site. FDA news release: FDA approves production of imaging agent that helps detect prostate cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319201.htm. Accessed February 25, 2013.
33. 18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645-7653.
34. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56-63.